The Future Of Gastroenterology Medicine
DHAT Research Institute, a division of Digestive Health Associates of Texas, P.A., brings the future of gastroenterology medicine to Adults and Pediatrics in the Dallas-Fort Worth area. We strive to provide all patients, current and new, with access to cutting edge treatments prior to them being granted FDA approved.
For new treatments and therapies to receive FDA approval, the investigational product must pass through four different phases: Phase 1, Phase 2 and Phase 3, are pre-FDA approval, while Phase 4 is considered post-FDA approval. DHAT Research Institute participates in all four Phases, 1 through 4, with our primary focus in Phase 2 and Phase 3 of the clinical research testing phase.
Months to Years
Years to Decades
Our current treatment options include but are not limited to the following conditions: Crohn’s Disease, Ulcerative Colitis, Inflammatory Bowel Disease, Irritable Bowel Syndrome, Celiac Disease, Gastroesophageal Reflux Disease or GERD, Gastroparesis, Non-alcoholic Steatohepatis or NASH, Fatty Liver Disease, Hepatitis B, Hepatitis C, Clostridium Difficile or C. Diff, Helicobacter Pylori, or H. Pylori, and Eosinophilic Esophagitis or EoE.
Please click on the Clinical Trials button above to see a list of enrolling clinical trials.